. Author manuscript; available in PMC: 2018 Apr 1.

Published in final edited form as: J Pediatr Hematol Oncol. 2017 Apr;39(3):e124–e130. doi: 10.1097/MPH.0000000000000793

Table I.

Levels of different bio-chemicals markers in 34 ALL patients

	Before treatment	Induction phase	Consolidation phase	Interval phase	Maintenance phase	p
WBC (10³ mm³)	5.6 ± 9.7^b	1.3 ± 3.1^a	5.4 ± 4^b	6 ± 2.5^b	4.8 ± 2^b	10⁻³
Lymphocytes (10³ mm³)	1.8 ± 5.8^a	3.5 ± 4.6^a	1.8 ± 1.1^a	1.5 ± 0.7^a	1.9 ± 0.9^a	0.16
Neutrophils (10³ mm³)	2.3 ± 4.7^a	1.1 ± 1.7^a	3 ± 3.7^a	3.8 ± 4.4^a	2.1 ± 1.1^a	0.07
Platelets (10³ mm3)	78.2 ± 104.7^a	79.5 ± 84^a	213.8 ± 113.2^b	230 ± 113.4^b	253 ± 104^b	10⁻³
Hb (g/dL)	8.2 ± 2.5^a	8.8 ± 2^a	10.3 ± 1.3^b	10.6 ± 1.6 ^b	11.7 ± 1.6 ^b	10⁻³
MCV (fL)	84 ± 9^a	84.7 ± 5.3^a	88.4 ± 6 ^b	87 ± 7.6^b	92 ±5.1^b	0.008
ALT (IU/L)	210.1±32^a	98.9 ± 33^a	38.3 ± 32^a	40.8 ±30^a	109.3 ± 25^a	0.47
AST (IU/L)	66.2 ± 32^a	36.4 ± 23^a	30.7 ± 16 ^a	34.2 ± 24.6^a	36.1 ± 34^a	0.06
ALP (IU/L)	208 ± 21^a	15405 ± 124^a	162.3 ± 38.3^a	147.1 ±79^a	184 ± 20^a	0.76
Creatinine (mmol/L)	42.4 ± 19.3^a	39.7± 17^a	34.9 ± 13^a	34.9 ± 16.3^a	35.6 ± 19^a	0.33
blood glucose (mmol/l)	5.6 ± 1.2^a	5.6 ± 1.2^a	5.4 ± 1.9^a	4.7 ± 1^a	5.4± 0.9^a	0.66
K (mEq/L)	4.2 ± 0.5^a	3.9 ± 0.4^a	4.1 ± 1.3^a	3.9 ±0.6 ^a	3.9 ± 1.1^a	0.55
Na (mEq/L)	138.7 ± 2.7^a	136.6 ± 2.7^a	139.4 ± 2.5^a	139.4 ±2.5^a	139 ± 4^a	0.32
Fibrinogen (g/L)	4 ± 1.4^a	3.2 ± 1.5^a	4.3 ± 2^a	4 ± 1.7^a	5.3 ± 1.2^a	0.09
Uric acid (mg/dL)	3.1 ± 1.6	2.1 ± 1.4	5.6 ± 6	-	-	-
Protidemia (g/L)	53.5 ± 9.3^a	53.3 ± 7^a	47 ± 3.3^a	52.6 ± 9.5^a	55.3 ± 5.5^a	0.11
Blasts in marrow (%)	88.6 ± 14.1	50.3 ± 37	42 ± 27.1	-	-	-

WBC: White blood cell, MCV: Mean corpuscular volume, ALT: alanine transaminase, AST: aspartate aminotransferase, ALP: alkaline phosphatase, K: potassium, Na: sodium. Each result represents mean ± S.D. Tukey’s multiple range test: groups that show different letters are statistically different (p <0.05).